Clinical research on the multi drug theray including LVFX against tuberculosis

Clinical research on the multi drug theray including LVFX against tuberculosis - research on treatment including LVFX against TB

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000008094

Enrollment

200

Registered

2012-06-04

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung tuberculosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Tuberculosis patients who are thought to be expected to use multi drug therapy including LVFX against tuberculosis for 6 months or longer

Exclusion criteria

Exclusion criteria: resistant tu LVFX or OFLX patients who are contraindicated to Cravit&reg;

Design outcomes

Primary

Measure	Time frame
The efficacy is measured by the proportion of negative conversion of tuberculosis bacilli. The safety is measured by the emergence of side effects (clinical findings and laboratory examination)	—

Countries

Japan

Contacts

Public ContactTakashi Yoshiyama

Research Institute of Tuberculosis Department of research

ryoken@jata.or.jp81-42-493-5711

Outcome results